Welcome to our dedicated page for Fmc SEC filings (Ticker: FMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The FMC Corporation (NYSE: FMC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a global agricultural sciences company focused on crop protection, biologicals, crop nutrition, and digital and precision agriculture, FMC uses its SEC reports to detail its financial condition, restructuring activities, capital structure and governance.
Investors can review current reports on Form 8-K, where FMC discloses material events such as quarterly earnings releases, leadership changes, restructuring initiatives and credit agreement amendments. For example, the company has filed 8-Ks describing quarterly financial results, the comprehensive Project Foundation cost optimization plan and Manufacturing Restructuring Program, and an amendment to its Fifth Amended and Restated Credit Agreement that adjusts leverage and interest coverage covenants and places conditions on dividends and indebtedness.
Through its periodic annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR and summarized on this page), FMC provides more detailed information on revenue by region, cost structure, research and development spending on new herbicide, insecticide and fungicide active ingredients, and risks related to competition, regulation and restructuring. These filings also describe the company’s geographic footprint, including its headquarters in Philadelphia, Pennsylvania, and its operations across North America, Latin America, Asia and EMEA.
The filings page also highlights governance and board-related disclosures, such as 8-K reports on director resignations or executive departures, and may include proxy materials that discuss executive compensation and board composition. For those monitoring capital structure and liquidity, filings related to credit facilities, covenant changes and potential asset sales—such as the planned divestiture of the India commercial business—are particularly relevant.
Stock Titan enhances these documents with AI-powered summaries that explain key points in plain language, helping users interpret complex sections of lengthy 10-Ks, 10-Qs and 8-Ks. Real-time updates from EDGAR ensure that new filings, including any Form 4 insider transaction reports or additional restructuring disclosures, appear promptly so investors can track how FMC’s financial and strategic decisions evolve over time.
Form 144 notice for FMC Corporation (FMC) reports a proposed sale of 1,510 common shares held in a brokerage account at Fidelity with an aggregate market value of $56,609.90. The shares were acquired on 09/27/2024 through restricted stock vesting as compensation, and the filer indicates an approximate sale date of 08/18/2025 on the NYSE. The filing shows 124,911,586 shares outstanding for context. No securities were reported sold by the filer in the past three months. The notice includes the standard representation that the seller has no undisclosed material adverse information.
FMC Corp. (FMC) Form 4: Director Carol Anthony Davidson reported the issuance of 113 common shares on 17 Jul 2025. The shares were granted at $0 cost as dividend-equivalent rights tied to previously vested restricted stock units. Following the transaction, Davidson’s direct holding rose to 13,085 shares. No derivative securities were exercised or disposed.
The filing reflects a routine, non-cash increase in insider ownership, signalling continued equity alignment but provides no indication of open-market buying or new strategic information. The size of the grant is immaterial relative to FMC’s average daily volume and market capitalization, so market impact is expected to be negligible.
On 21 Jul 2025 FMC Corporation (FMC) filed a Form 4 for director C. Scott Greer covering a 17 Jul 2025 transaction. Greer was credited with 388 common shares via dividend-equivalent rights tied to previously vested restricted stock units; no cash was paid (reported price $0). His direct beneficial ownership rose to 73,809 shares.
No common-stock sales, option exercises or new derivatives were disclosed, and board roles remain unchanged. The automatic share issuance represents less than 0.0003 % of FMC’s ~128 million shares outstanding, making the event routine and immaterial to valuation or governance considerations.
FMC Corporation (FMC) – Form 4 Insider Transaction
Director K’Lynne Johnson reported receipt of 339 common shares on 17 Jul 2025. The shares were issued at $0 as dividend-equivalent rights linked to previously vested RSUs. Post-transaction direct ownership rises to 34,569 shares. No open-market purchases, sales, or derivative positions were disclosed, and Johnson remains classified solely as a director.
The move represents a routine administrative increase that is immaterial relative to FMC’s share count and unlikely to affect valuation or control dynamics.
FMC Corp – Form 4 insider filing: Director Dirk A. Kempthorne reported one transaction dated 07/17/2025. He acquired 614 common shares at a stated price of $0, issued as dividend-equivalent rights linked to previously vested restricted stock units. Post-transaction, his direct ownership increases to 55,760 shares. No shares were sold and no derivative securities were exercised or disposed. The filing reflects a modest, non-cash addition representing well under 1 % of both Kempthorne’s stake and FMC’s total shares outstanding, therefore unlikely to be market-moving. No financial results, guidance, or other corporate events are included in this filing.
FMC Corp (FMC) – Form 4 filed 21-Jul-2025
Director Steven T. Merkt reported the automatic acquisition of 34 common shares on 17-Jul-2025 at $0 cost. The shares were issued as dividend-equivalent rights tied to previously-vested restricted stock units. After the transaction Merkt directly owns 5,809 FMC shares. No derivative securities were exercised, and there were no open-market buys or sales.
The transaction is immaterial in size—roughly 0.00004 % of FMC’s outstanding shares—and appears to be routine administrative settlement rather than an active investment decision. Accordingly, it provides only a limited signal about insider sentiment or the company’s near-term fundamentals.